Broadens the definition of 'valuable consideration' to include more forms of compensation and costs related to fetal tissue, making it harder for abortion providers to receive any payment or benefit from fetal tissue without violating the prohibition, which restricts access to and funding mechanisms
The term `valuable consideration' includes-- (A) any payment made or debt incurred; (B) any gift, honorarium, or recognition of value bestowed; (C) any price, charge, or fee which is waived, forgiven, reduced, or indefinitely delayed; (D) any loan or debt which is canceled or otherwise forgiven; (E) the transfer of any item from one person to another or provision of any service or granting of any opportunity for which a charge is customarily made, without charge or for a reduced charge; and (F) any payments associated with the transportation, implantation, processing, preservation, quality
✓ Quote verified word for word in the bill text
Abortionpersonhood ivfAI label
↓Restricts abortion accessmodel confidence 60%
Expands the prohibition on transactions relating to human fetal tissue by broadening what counts as 'valuable consideration' to cover more activities and benefits, which could affect handling of fetal tissue from abortions and potentially impact IVF or related practices involving embryonic or fetal
Section 498B(e) of the Public Health Service Act (42 U.S.C. 289g- 2(e)) is amended by striking paragraph (3) and inserting the following new paragraph: ``(3) The term `valuable consideration' includes--
✓ Quote verified word for word in the bill text
Introduced (completed)
Committee
Passed one chamber
Passed both
President
Law
Stage: Committee · step 2 of 6
Last action
2025-01-24: Referred to the House Committee on Energy and Commerce.
Why the model tagged it this way: The bill amends federal law to broaden the definition of 'valuable consideration' in the context of prohibiting sales or transactions involving human fetal tissue, which is directly tied to abortion procedures. This change restricts abortion-related activities by closing perceived loopholes that allow providers to receive payments or benefits associated with fetal tissue, falling under abortion funding/insurance and personhood/IVF categories due to its impact on tissue handling and potential downstream effects.
Related bills
HR10600Abortion is Health Care Everywhere Act of 2026↑Expands abortion access↑Expands abortion access Committee
S5565Abortion is Health Care Everywhere Act of 2026↑Expands abortion access↑Expands abortion access Committee
HR9941Right to IVF Act of 2026↑Expands abortion access Committee
S5108Right to IVF Act of 2026↑Expands abortion access Committee